<?xml version="1.0" encoding="UTF-8"?>
<p>On April 2018, the Strategic Advisory Group of Experts on Immunization recommended that countries, which are considering the introduction of DengvaxiaÂ® to control dengue infection, must conduct a pre-vaccination screening and only dengue-seropositive persons should be vaccinated. Moreover, vaccination should be considered as part of an integrated dengue prevention and control strategy together, along with a well-executed and sustained vector control (
 <xref rid="B27" ref-type="bibr">27</xref>). In addition, seronegative travelers from non-dengue endemic countries should not receive this vaccine, because the vaccine could predispose them to more severe dengue if they were exposed to a natural infection (
 <xref rid="B28" ref-type="bibr">28</xref>).
</p>
